Evidence map›Paper›PMID 31189595›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2019

Apelin protects against abdominal aortic aneurysm and the therapeutic role of neutral endopeptidase resistant apelin analogs.

Wang Wang, Mengcheng Shen, Conrad Fischer, Ratnadeep Basu, Saugata Hazra, Pierre Couvineau, Manish Paul, Faqi Wang, Sandra Toth, Doran S Mix and 7 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 62 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Endogenous Vasoactive Peptides and Vascular Aging-Related Diseases.Oxidative medicine and cellular longevity · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 3 countries.

Wang WangDivision of Cardiology, Department of Medicine, University of Alberta, Edmonton, AB T6G 2G3, Canada.
Mengcheng ShenMazankowski Alberta Heart Institute, University of Alberta, Edmonton, AB T6G 2J2, Canada.
Conrad FischerDepartment of Chemistry, University of Alberta, Edmonton, AB T6G 2N4, Canada.
Ratnadeep BasuDivision of Cardiology, Department of Medicine, University of Alberta, Edmonton, AB T6G 2G3, Canada.
Saugata HazraDepartment of Biotechnology, Indian Institute of Technology, 247667 Roorkee, Uttarakhand, India.
Pierre CouvineauDepartment of Biochemistry and Molecular Medicine, Faculty of Medicine, University of Montreal, Montreal, QC H3C 3J7, Canada.
Manish PaulDepartment of Biotechnology, North Orissa University, 757003 Baripada, Odisha, India.
Faqi WangDivision of Cardiology, Department of Medicine, University of Alberta, Edmonton, AB T6G 2G3, Canada.
Sandra TothDivision of Vascular Surgery, University of Rochester, Rochester, NY 14642.
Doran S MixDivision of Vascular Surgery, University of Rochester, Rochester, NY 14642.
Marko PoglitschAttoquant Diagnostics, 1030 Vienna, Austria.
Norma P GerardBoston Children's Hospital, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115.
Michel BouvierDepartment of Biochemistry and Molecular Medicine, Faculty of Medicine, University of Montreal, Montreal, QC H3C 3J7, Canada.ORCID 0000-0003-1128-0100
John C VederasDepartment of Chemistry, University of Alberta, Edmonton, AB T6G 2N4, Canada.
Josef M PenningerDepartment of Medical Genetics, Life Sciences Institute, University of British Columbia, Vancouver, BC V6H 3N1, Canada.
Zamaneh KassiriMazankowski Alberta Heart Institute, University of Alberta, Edmonton, AB T6G 2J2, Canada.
Gavin Y OuditDivision of Cardiology, Department of Medicine, University of Alberta, Edmonton, AB T6G 2G3, Canada; gavin.oudit@ualberta.ca.
University of Alberta · CAUniversité de Montréal · CAUniversity of Rochester · USBoston Children's Hospital · USIndian Institute of Technology Roorkee · INMaharaja Sriram Chandra Bhanja Deo University · INUniversity of British Columbia · CA

Funding

CIHR 136921CIHR PJT153306
6 · The paper itself

Abstract

Abdominal aortic aneurysm (AAA) remains the second most frequent vascular disease with high mortality but has no approved medical therapy. We investigated the direct role of apelin (APLN) in AAA and identified a unique approach to enhance APLN action as a therapeutic intervention for this disease. Loss of APLN potentiated angiotensin II (Ang II)-induced AAA formation, aortic rupture, and reduced survival. Formation of AAA was driven by increased smooth muscle cell (SMC) apoptosis and oxidative stress in

Indexed as

AgedAged, 80 and overAngiotensin-Converting Enzyme 2Angiotensin IIAnimalsAorta, AbdominalAortic Aneurysm, AbdominalApelinApoptosisCardiovascular AgentsDiet, High-FatDisease Models, AnimalFemaleGene Knockdown TechniquesHumansMaleACE2 protein, humanAce2 protein, mouseAngiotensin-Converting Enzyme 2Angiotensin IIApelinAPLN protein, humanApln protein, mouseCardiovascular AgentsLDLR protein, humanNeprilysinPeptidyl-Dipeptidase APhenylephrineReceptors, LDLRNA, Small InterferingACE2aneurysmangiotensin IIapelinneutral endopeptidase

Identifiers

PMID31189595
PMCPMC6600956
OpenAlexW2951923805

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.